GLP-1 Weight Loss Drugs Pose Hidden Muscle Loss Risk for Adults Over 65, Researchers Warn
Researchers are raising concerns about muscle loss in older adults taking GLP-1 drugs like Ozempic and Wegovy. Studies show these medications can cause 15 to 40 percent of total weight loss to come from lean muscle mass, which is especially dangerous for people already at risk for age-related muscle decline.
GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are effective at reducing weight, but researchers are warning that a significant portion of that weight loss comes from muscle, not fat, creating serious risks for adults over 65.
Studies show that lean body mass loss can account for 15 to 40 percent of total weight lost on GLP-1 medications, and some estimates put that figure as high as 60 percent in certain patients. For older adults, who already lose 12 to 16 percent of muscle mass as a natural part of aging, this drug-induced loss can push them toward dangerous levels of frailty.
Researchers at Stanford Medicine identified a drug class called PGDHi, including a compound called MF-300, that may help preserve muscle regeneration in patients taking GLP-1 drugs. A separate clinical trial called BELIEVE tested bimagrumab, a monoclonal antibody, in combination with semaglutide. That combination increased fat loss while preserving or improving lean mass compared to semaglutide alone.
Scientists are also developing continuous protein sensors to track muscle breakdown in real time. One proof-of-concept study used an aptamer-based biosensor to monitor phenylalanine levels, a biomarker for muscle loss, giving clinicians a potential tool to catch problems early.
Current clinical guidance recommends that older adults on GLP-1 therapy pair the medication with consistent resistance training and higher protein intake. Experts also recommend baseline assessments of muscle mass and physical function before starting treatment.
The medical community is increasingly focused on the quality of weight loss, not just the total amount. Researchers say the biggest gap in the field is the lack of long-term randomized trials specifically targeting older populations, who face the greatest risk from sarcopenia.
